Identification
- Summary
Lisdexamfetamine is a central nervous system (CNS) stimulant used to treat attention deficit hyperactivity disorder (ADHD) and moderate to severe eating disorders.
- Brand Names
- Vyvanse
- Generic Name
- Lisdexamfetamine
- DrugBank Accession Number
- DB01255
- Background
Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant known as d-amphetamine,3 covalently attached to the naturally occurring amino acid L-lysine.1 Lisdexamfetamine is the first chemically formulated prodrug stimulant 3 and was first approved by the FDA in April 2008.1 It was also approved by Health Canada in February 2009.7 Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder 1 by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.6
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Lisdexamfetamine (DB01255)
- Weight
- Average: 263.3785
Monoisotopic: 263.199762437 - Chemical Formula
- C15H25N3O
- Synonyms
- Lisdexamfetamine
Pharmacology
- Indication
Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients six years and older. It is also indicated to treat moderate to severe binge eating disorder (BED) in adults.6,7 It is approved for use in the US and Canada.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Adhd •••••••••••• ••••••••••• •••••• ••••••••• Management of Moderate binge eating disorder (bed) •••••••••••• ••••• Management of Severe binge eating disorder (bed) •••••••••••• ••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Once administered, lisdexamfetamine is converted to its active metabolite, dextroamphetamine, which is taken up by the brain. Dextroamphetamine blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases the release of these monoamines into the extraneuronal space. The parent drug, lisdexamfetamine, does not bind to the sites responsible for the reuptake of norepinephrine and dopamine in vitro.6
- Mechanism of action
Lisdexamfetamine is a prodrug of dextroamphetamine, which is a noncatecholamine sympathomimetic amine with CNS stimulant activity. Dextroamphetamine is a known inhibitor of the dopamine transporter (DAT), noradrenaline transporter (NET) and vesicular monoamine transporter 2 (VMAT2), with a weaker affinity for the serotonin transporter (SERT). It is also a weak monoamine oxidase (MAO) inhibitor.4 Dextroamphetamine ultimately blocks the reuptake of norepinephrine and dopamine into the presynaptic neuron and increases catecholamine availability in the extracellular space.6
The exact mode of therapeutic action of lisdexamfetamine in ADHD and BED has not been fully elucidated; however, the clinical effects of lisdexamfetamine are believed to be linked to the pharmacological actions of dextroamphetamine.4,6
Target Actions Organism UTrace amine-associated receptor 1 agonistHumans - Absorption
After oral administration, lisdexamfetamine dimesylate is rapidly absorbed from the gastrointestinal tract.3,7 Following single-dose oral administration of lisdexamfetamine in pediatric patients with ADHD under fasted conditions, Tmax of lisdexamfetamine and dextroamphetamine was reached at approximately one hour and 3.5 hours post-dose, respectively. Weight/Dose normalized AUC and Cmax values were the same in pediatric patients as the adults. Food prolongs Tmax by approximately one hour and may decrease the exposure (Cmax and AUC) of dextroamphetamine.6
- Volume of distribution
Dextroamphetamine, the active metabolite of lisdexamfetamine, easily crosses the blood-brain barrier.4
- Protein binding
Not Available
- Metabolism
Lisdexamfetamine dimesylate is hydrolyzed by red blood cells to dextroamphetamine and l-lysine primarily in the blood. Substantial hydrolysis occurs even at low hematocrit levels.3,4,6 Dextroamphetamine can further be metabolized to form other metabolites, such as hippuric acid.5
Lisdexamfetamine is not metabolized by cytochrome P450 enzymes.2,6
Hover over products below to view reaction partners
- Route of elimination
Following oral administration of a 70 mg dose of radiolabeled lisdexamfetamine dimesylate in six healthy subjects, approximately 96% of the oral dose radioactivity was recovered in the urine, and only 0.3% recovered in the feces over 120 hours. Of the radioactivity recovered in the urine, 42% of the dose was related to amphetamine, 25% to hippuric acid, and 2% to intact lisdexamfetamine.6
- Half-life
Plasma concentrations of unconverted lisdexamfetamine are low and transient, generally becoming non-quantifiable by 8 hours after administration. The plasma elimination half-life of lisdexamfetamine typically averaged less than one hour in volunteers ages six years and older. The plasma elimination half-life of dextroamphetamine was approximately 8.6 to 9.5 hours in pediatric patients six to 12 years and 10 to 11.3 hours in healthy adults.6
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The LD50 value for lisdexamfetamine dihydrochloride in rats was >1000 mg/kg.7
Manifestations of amphetamine overdose include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Serotonin syndrome has been reported with amphetamine use, including lisdexamfetamine. Cardiovascular effects include arrhythmias, hypertension or hypotension and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Convulsions and coma usually precede fatal poisoning. Lisdexamfetamine and d-amphetamine are not dialyzable.6
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbiraterone The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Abiraterone. Acebutolol The serum concentration of dextroamphetamine, an active metabolite of Lisdexamfetamine, can be increased when used in combination with Acebutolol. Aceclofenac The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when Lisdexamfetamine is combined with Acemetacin. Acetazolamide Acetazolamide may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level. - Food Interactions
- Avoid antacids. Urinary excretion of lisdexamfetamine is elevated when the urine is more acidic. Antacids like sodium bicarbonate alkalinize the urine; therefore, they may reduce lisdexamfetamine elimination.
- Limit foods and supplements high in vitamin C. Urinary excretion of lisdexamfetamine is elevated when the urine is more acidic. Vitamin C acidifies the urine and, therefore, may increase lisdexamfetamine elimination.
- Take with or without food. Food prolongs Tmax by approximately one hour, but does not significantly affect drug exposure.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Lisdexamfetamine dimesylate SJT761GEGS 608137-33-3 CETWSOHVEGTIBR-FORAGAHYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Vyvanse Capsule 70 mg/1 Oral Physicians Total Care, Inc. 2010-03-04 Not applicable US 
Vyvanse Tablet, chewable 30 mg/1 Oral Takeda Pharmaceuticals America, Inc. 2017-01-28 Not applicable US Vyvanse Tablet, chewable 50 mg Oral Takeda 2019-08-06 Not applicable Canada 
Vyvanse Capsule 50 mg/1 Oral Physicians Total Care, Inc. 2008-07-11 Not applicable US Vyvanse Capsule 70 mg/1 Oral Takeda Pharmaceuticals America, Inc. 2007-02-23 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Lisdexamfetamine Dimesylate Capsule 10 mg/1 Oral Sun Pharmaceutical Industries, Inc. 2023-08-25 Not applicable US Lisdexamfetamine Dimesylate Capsule 50 mg/1 Oral Amneal Pharmaceuticals LLC 2023-08-28 Not applicable US Lisdexamfetamine Dimesylate Tablet, chewable 40 mg/1 Oral Ascent Pharmaceuticals, Inc 2023-08-25 Not applicable US Lisdexamfetamine Dimesylate Capsule 20 mg/1 Oral Apotex Corp. 2023-11-09 Not applicable US Lisdexamfetamine Dimesylate Capsule 30 mg/1 Oral Hikma Pharmaceuticals USA Inc. 2023-08-25 Not applicable US
Categories
- ATC Codes
- N06BA12 — Lisdexamfetamine
- Drug Categories
- Agents producing tachycardia
- Agents that produce hypertension
- Amines
- Amphetamines
- Central Nervous System Agents
- Central Nervous System Stimulants
- Central Nervous System Stimulation
- Centrally Acting Sympathomimetics
- Dopamine Agents
- Dopamine Uptake Inhibitors
- Ethylamines
- Membrane Transport Modulators
- Nervous System
- Neurotransmitter Agents
- Neurotransmitter Uptake Inhibitors
- Phenethylamines
- Psychoanaleptics
- Psychostimulants, Agents Used for ADHD and Nootropics
- Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
- Sympathomimetics
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acid amides
- Alternative Parents
- Amphetamines and derivatives / Phenylpropanes / N-acyl amines / Secondary carboxylic acid amides / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Alpha-amino acid amide / Amine / Amphetamine or derivatives / Aromatic homomonocyclic compound / Benzenoid / Carbonyl group / Carboxamide group / Fatty acyl / Fatty amide / Hydrocarbon derivative
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- H645GUL8KJ
- CAS number
- 608137-32-2
- InChI Key
- VOBHXZCDAVEXEY-JSGCOSHPSA-N
- InChI
- InChI=1S/C15H25N3O/c1-12(11-13-7-3-2-4-8-13)18-15(19)14(17)9-5-6-10-16/h2-4,7-8,12,14H,5-6,9-11,16-17H2,1H3,(H,18,19)/t12-,14-/m0/s1
- IUPAC Name
- (2S)-2,6-diamino-N-[(2S)-1-phenylpropan-2-yl]hexanamide
- SMILES
- C[C@@H](CC1=CC=CC=C1)NC(=O)[C@@H](N)CCCCN
References
- Synthesis Reference
Michael J. Bauer, Gary Richard Callen, Judi Christine Humphrey, Todd Jeffrey Johnson, Matthew Wendell Schiesher, "Methods and Compositions for Preparing Lisdexamfetamine and Salts Thereof." U.S. Patent US20120157706, issued June 21, 2012.
US20120157706- General References
- Madaan V: Lisdexamfetamine dimesylate for childhood ADHD. Drugs Today (Barc). 2008 May;44(5):319-24. doi: 10.1358/dot.2008.44.5.1215724. [Article]
- Krishnan S, Moncrief S: An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos. 2007 Jan;35(1):180-4. Epub 2006 Oct 11. [Article]
- Goodman DW: Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P T. 2010 May;35(5):273-87. [Article]
- Hutson PH, Pennick M, Secker R: Preclinical pharmacokinetics, pharmacology and toxicology of lisdexamfetamine: a novel d-amphetamine pro-drug. Neuropharmacology. 2014 Dec;87:41-50. doi: 10.1016/j.neuropharm.2014.02.014. Epub 2014 Mar 1. [Article]
- Krishnan SM, Pennick M, Stark JG: Metabolism, distribution and elimination of lisdexamfetamine dimesylate: open-label, single-centre, phase I study in healthy adult volunteers. Clin Drug Investig. 2008;28(12):745-55. doi: 10.2165/0044011-200828120-00002. [Article]
- FDA Approved Drug Products: VYVANSE (lisdexamfetamine dimesylate) capsules and chewable tablets, for oral use, CII (January 2022) [Link]
- Health Canada Approved Drug Products: VYVANSE (lisdexamfetamine dimesylate) Oral Capsules [Link]
- External Links
- Human Metabolome Database
- HMDB0015385
- PubChem Compound
- 11597698
- PubChem Substance
- 46505358
- ChemSpider
- 9772458
- 700810
- ChEBI
- 135925
- ChEMBL
- CHEMBL1201222
- ZINC
- ZINC000011680943
- Therapeutic Targets Database
- DAP000571
- PharmGKB
- PA164748975
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Lisdexamfetamine
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Completed Not Available Attention Deficit Hyperactivity Disorder (ADHD) 1 4 Completed Basic Science Attention Deficit Hyperactivity Disorder (ADHD) 2 4 Completed Other Attention Deficit Hyperactivity Disorder (ADHD) 1 4 Completed Treatment ADHD - Inattentive Type / Traumatic Brain Injury (TBI) 1 4 Completed Treatment ADHD Specifically With Executive Function Impairment 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- New River Pharmaceuticals Inc.
- Patheon Inc.
- Physicians Total Care Inc.
- Quality Care
- Shire Inc.
- Dosage Forms
Form Route Strength Capsule, coated Oral 70 mg Capsule, coated Oral 30 mg Capsule, coated Oral 50 mg Capsule Oral 10 mg/1 Capsule Oral 10 mg Capsule Oral 20 mg/1 Capsule Oral 20 mg Capsule Oral 30 mg/1 Capsule Oral 30 mg Capsule Oral 30.000 mg Capsule Oral 40 mg Capsule Oral 40 mg/1 Capsule Oral 50 mg Capsule Oral 50 mg/1 Capsule Oral 60 mg Capsule Oral 60 mg/1 Capsule Oral 70 mg Capsule Oral 70 mg/1 Tablet, chewable Oral 10 mg/1 Tablet, chewable Oral 10 mg Tablet, chewable Oral 20 mg/1 Tablet, chewable Oral 20 mg Tablet, chewable Oral 30 mg/1 Tablet, chewable Oral 30 mg Tablet, chewable Oral 40 mg Tablet, chewable Oral 40 mg/1 Tablet, chewable Oral 50 mg Tablet, chewable Oral 50 mg/1 Tablet, chewable Oral 60 mg Tablet, chewable Oral 60 mg/1 Capsule Oral 20.0 mg Capsule Oral 30.0 mg Capsule Oral 40.0 mg Capsule Oral 50.0 mg Capsule Oral 60.0 mg Capsule Oral 70.0 mg Capsule, coated Oral 20 mg Capsule, coated Oral 40 mg Capsule, coated Oral 60 mg - Prices
Unit description Cost Unit Vyvanse 30 mg capsule 6.24USD capsule Vyvanse 50 mg capsule 6.02USD capsule Vyvanse 70 mg capsule 5.85USD capsule Vyvanse 40 mg capsule 5.8USD capsule Vyvanse 20 mg capsule 5.26USD capsule Vyvanse 60 mg capsule 5.02USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7659253 Yes 2010-02-09 2023-08-24 US US7718619 Yes 2010-05-18 2023-08-24 US US7659254 Yes 2010-02-09 2023-08-24 US US7671030 Yes 2010-03-02 2023-08-24 US US7662788 Yes 2010-02-16 2023-08-24 US US7687467 Yes 2010-03-30 2023-08-24 US US7678770 Yes 2010-03-16 2023-08-24 US US7671031 Yes 2010-03-02 2023-08-24 US US7713936 Yes 2010-05-11 2023-08-24 US US7674774 Yes 2010-03-09 2023-08-24 US US7678771 Yes 2010-03-16 2023-08-24 US US7655630 Yes 2010-02-02 2023-08-24 US US7687466 Yes 2010-03-30 2023-08-24 US US7223735 Yes 2007-05-29 2023-08-24 US US7700561 Yes 2010-04-20 2023-08-24 US US7662787 Yes 2010-02-16 2023-08-24 US US7723305 Yes 2010-05-25 2023-08-24 US US7105486 Yes 2006-09-12 2023-08-24 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 191-193 https://www.trc-canada.com/prod-img/MSDS/L468885MSDS.pdf water solubility 792 mg/mL https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021977s048,208510s005lbl.pdf logP -1.76 https://www.tga.gov.au/sites/.../auspar-lisdexamfetamine-dimesilate-131023-pi.docx pKa 10.5 https://www.tga.gov.au/sites/.../auspar-lisdexamfetamine-dimesilate-131023-pi.docx - Predicted Properties
Property Value Source Water Solubility 0.0877 mg/mL ALOGPS logP 1.01 ALOGPS logP 1.14 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 15.89 Chemaxon pKa (Strongest Basic) 10.21 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 3 Chemaxon Polar Surface Area 81.14 Å2 Chemaxon Rotatable Bond Count 8 Chemaxon Refractivity 78.31 m3·mol-1 Chemaxon Polarizability 31.28 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9858 Blood Brain Barrier + 0.9444 Caco-2 permeable + 0.664 P-glycoprotein substrate Substrate 0.6919 P-glycoprotein inhibitor I Non-inhibitor 0.9264 P-glycoprotein inhibitor II Non-inhibitor 0.9802 Renal organic cation transporter Non-inhibitor 0.8398 CYP450 2C9 substrate Non-substrate 0.8303 CYP450 2D6 substrate Non-substrate 0.621 CYP450 3A4 substrate Non-substrate 0.7228 CYP450 1A2 substrate Non-inhibitor 0.7025 CYP450 2C9 inhibitor Non-inhibitor 0.9337 CYP450 2D6 inhibitor Non-inhibitor 0.858 CYP450 2C19 inhibitor Non-inhibitor 0.7568 CYP450 3A4 inhibitor Non-inhibitor 0.5499 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8494 Ames test Non AMES toxic 0.7156 Carcinogenicity Non-carcinogens 0.854 Biodegradation Not ready biodegradable 0.8575 Rat acute toxicity 2.0058 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9688 hERG inhibition (predictor II) Non-inhibitor 0.9004
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0udi-7910000000-cf67fb00e86045c2e167 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-03di-0290000000-24fbe6074a7ff645887c Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03gl-2890000000-f4bffe135c3f75f90f40 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-001i-6940000000-704d606c65e51f253bee Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-005d-9810000000-027326415aaf04017fdc Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-9200000000-0887b5e4f9bbe3580fd8 Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-9300000000-b66be0a84f8848fbc99a Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 171.9992286 predictedDarkChem Lite v0.1.0 [M-H]- 170.5049286 predictedDarkChem Lite v0.1.0 [M-H]- 164.69353 predictedDeepCCS 1.0 (2019) [M+H]+ 172.1414286 predictedDarkChem Lite v0.1.0 [M+H]+ 170.7083286 predictedDarkChem Lite v0.1.0 [M+H]+ 167.08965 predictedDeepCCS 1.0 (2019) [M+Na]+ 172.3272286 predictedDarkChem Lite v0.1.0 [M+Na]+ 170.6377286 predictedDarkChem Lite v0.1.0 [M+Na]+ 173.47252 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Trace-amine receptor activity
- Specific Function
- Receptor for trace amines, including beta-phenylethylamine (b-PEA), p-tyramine (p-TYR), octopamine and tryptamine, with highest affinity for b-PEA and p-TYR. Unresponsive to classical biogenic amin...
- Gene Name
- TAAR1
- Uniprot ID
- Q96RJ0
- Uniprot Name
- Trace amine-associated receptor 1
- Molecular Weight
- 39091.34 Da
References
- Miller GM: The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. J Neurochem. 2011 Jan;116(2):164-76. doi: 10.1111/j.1471-4159.2010.07109.x. [Article]
- Liu JF, Li JX: TAAR1 in Addiction: Looking Beyond the Tip of the Iceberg. Front Pharmacol. 2018 Mar 27;9:279. doi: 10.3389/fphar.2018.00279. eCollection 2018. [Article]
- Pei Y, Asif-Malik A, Canales JJ: Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications. Front Neurosci. 2016 Apr 5;10:148. doi: 10.3389/fnins.2016.00148. eCollection 2016. [Article]
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- Curator comments
- These data are based on in vitro studies.
- General Function
- Proton-dependent oligopeptide secondary active transmembrane transporter activity
- Specific Function
- Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
- Gene Name
- SLC15A1
- Uniprot ID
- P46059
- Uniprot Name
- Solute carrier family 15 member 1
- Molecular Weight
- 78805.265 Da
References
Drug created at May 15, 2007 01:24 / Updated at September 28, 2023 05:40